Trial has met primary endpoints of safety and immunogenicity and secondary endpoint for efficacy based on response rate
Proceeds Will Fund Completion of GT-30 Trial of Personalized Therapeutic Cancer Vaccine in Liver Cancer
By RECIST1.1, Three Complete Responses and Seven Durable Partial Responses Achieved to Date--
Nomination Recognizes Progress and Promise of Geneos' Personalized Therapeutic Cancer Vaccines
Proceeds to Fund Expansion of Phase 1b/2a Trial of Personalized Therapeutic Cancer Vaccine in Liver Cancer
To Date, Four Patients Are Now Cancer Free Out of 23 Evaluable
Overall Response Rate 30.4 Percent in 23 Evaluable Patients Including Two Complete Responses and a Third Cancer-Free Patient
Encouraging Safety and Efficacy Data from Ongoing GT-30 Study in Second-Line HCC
Company Bolsters Management Team in Advance of Phase 2 Data Announcement and Preparations for Potential Registrational Clinical Trial
Geneos expands its Phase Ib/IIa clinical trial in lead indication for treating patients with advanced hepatocellular carcinoma
Geneos Therapeutics announced positive preliminary results of its ongoing first-in-human trial.
Texas-based GMP Plasmid CDMO VGXI, Inc. and Geneos Therapeutics, Inc. Expand their Clinical Manufacturing Supply Agreement in Support of Geneos’ Ongoing GT-30 Phase Ib/IIa Clinical Trial for advanced hepatocellular carcinoma (HCC)
Geneos Therapeutics has closed its Series A1 round, raising $12 million in financing.
VGXI, Inc., Geneos Therapeutics’ CDMO partner, completes manufacturing of first GMP Lot under Clinical Manufacturing Supply Agreement.
Geneos Therapeutics announced that its personalized neoantigen-targeting vaccine, GNOS-PV02 (based on its proprietary GT-EPIC™ platform), will be evaluated in a clinical trial for patients with advanced Hepatocellular Carcinoma (HCC).
VGXI and Geneos Therapeutics have entered into a long-term master supply agreement to establish small-scale and rapid turnaround production services ideally suited for the personalized therapy approach.